Episode 015: The Age Reversal Trial — Sinclair, Hype, and the Eye of the Storm

Why it matters. The FDA has cleared the first-ever human trial of a therapy designed to partially reverse cellular aging. Life Biosciences' ER-100, an epigenetic reprogramming treatment targeting serious vision loss, marks the leap from decades of mouse studies to an actual Phase 1 human trial. The episode dissects the science, the hype, and the complicated legacy of the man behind it — asking whether partial cellular reprogramming is the breakthrough longevity researchers have promised or another cycle of premature optimism in a field prone to it.

Life Biosciences / Harvard Medical School. The trial is registered on ClinicalTrials.gov (NCT07290244). The foundational research was published in Nature (2020) demonstrating recovery of youthful epigenetic information and restored vision in mice. Coverage from Fortune, MIT Technology Review, Lifespan.io, and Longevity.technology. A summary of Sinclair's World Government Summit 2026 talk provides additional context on the "Information Theory of Aging." The Wall Street Journal investigation (2024) into Sinclair's business track record offers critical counterweight. The demographic claim about cancer and lifespan traces to a 1990 LA Times report.

The Researchers. David Sinclair is a professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research, best known for his work on sirtuins, NAD+, and resveratrol. The foundational Yamanaka factor work was done by Shinya Yamanaka, who won the 2012 Nobel Prize in Physiology or Medicine for discovering that mature cells can be reprogrammed to pluripotent stem cells. The 2020 Nature paper's lead authors include Yuancheng Lu and Bruce Bhatt, with senior authorship from Sinclair.

Key Technical Concepts. The trial centers on partial epigenetic reprogramming — using a subset of Yamanaka factors (OCT4, SOX2, KLF4, delivered via AAV vector) to rejuvenate cells without fully dedifferentiating them. The underlying hypothesis is Sinclair's Information Theory of Aging, which posits that aging is driven by epigenetic noise — the progressive loss of gene-regulatory information — rather than genomic mutations. The 2020 mouse study demonstrated that this approach could restore DNA methylation patterns to a younger state and recover lost vision in aged mice and glaucoma models. The critical open question is whether partial reprogramming in humans can achieve rejuvenation without triggering teratoma formation, the cancer risk inherent in full cellular reprogramming.

Daily Tech Feed: From the Labs is available on Apple Podcasts, Spotify, and wherever fine podcasts are distributed. Visit us at pod.c457.org for all our shows. New episodes daily.